Ultragenyx Pharmaceutical
RARE
#4150
Rank
NZ$5.33 B
Marketcap
NZ$54.12
Share price
-0.55%
Change (1 day)
-9.74%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2026 (TTM): -NZ$0.92 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are NZ$0.66 Billion. In 2025 the company made an earning of -NZ$0.91 Billion a decrease over its 2024 earnings that were of -NZ$0.9 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -NZ$0.92 Billion2.02%
2025 -NZ$0.91 Billion1%
2024 -NZ$0.9 Billion-6.99%
2023 -NZ$0.96 Billion-17.65%
2022 -NZ$1.17 Billion55.52%
2021 -NZ$0.75 Billion178.53%
2020 -NZ$0.27 Billion-59.64%
2019 -NZ$0.67 Billion1.46%
2018 -NZ$0.66 Billion12.9%
2017 -NZ$0.59 Billion32.63%
2016 -NZ$0.44 Billion67.87%
2015 -NZ$0.27 Billion160.2%
2014 -NZ$0.11 Billion66.64%
2013 -NZ$60.27 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Lexicon Pharmaceuticals
LXRX
-NZ$0.13 Billion-87.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-NZ$48.54 Million-94.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
NZ$0.33 M-100.04%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
NZ$0.68 B-171.86%๐Ÿ‡บ๐Ÿ‡ธ USA